Table 2.
Microsomal prostaglandin E synthase-1 overexpression in human cancers.
| Cancer type | Percentage | Detection methods | Ref. |
|---|---|---|---|
| Colorectal cancer | 83% (15/18)† | IHC‡+WB§ | [39] |
| 96% (81/84) | IHC | [40] | |
| Non-small-cell lung cancer | 79% (15/19) | IHC+WB | [52] |
| 66% (61/93) | IHC+WB+RT-PCR¶ | [54] | |
| 70% (55/79) | IHC+WB | [53] | |
| Gastric adenoma | 79% (23/29)# 82% (14/17)†† 100%‡‡ |
IHC | [38] |
| Gastric cancer (Helicobacter pylori related) | 44% (22/50)§§ 66% (55/84)¶¶ |
IHC | [35] |
| Gastric cancer | 33% (15/45) | IHC+WB | [36] |
| 47% (60/129) | IHC+WB | [37] | |
| Head and neck squamous cell carcinoma | 79% (11/14) | IHC+WB | [50] |
| 84% (21/25) | IHC+RT-PCR | [49] | |
| Squamous cell carcinoma of the penis | 100% (16/16) | IHC+WB | [51] |
| Squamous cell carcinoma of the larynx | 92% (23/24) | IHC | [55] |
| Squamous cell carcinoma of the uterine cervix | 46% (7/15) | IHC | [56] |
| Breast cancer | 79% (70/89) | IHC | [46] |
| Ovarian adenocarcinoma | Not specified | IHC+WB | [58] |
| Hepatocelluar carcinoma | Not specified 39% (7/18)## 35% (14/40)††† 0% (0/6)‡‡‡ |
IHC+WB+RT-PCR IHC |
[41] [42] |
| Renomedullary interstitial cell tumors | 86% (12/14) | IHC | [47] |
| Pancreatic cancer | 71% (5/7) | IHC+WB+RT-PCR | [43] |
| Barrett’s esophageal | 100% (123/123) | RT-PCR | [34] |
| Glioma | Not specified | IHC | [44] |
| Medulloblastoma | 100% (39/39) | IHC | [45] |
| Papillary thyroid carcinoma | 95% (19/20) | IHC | [48] |
| Endometrial adenocarcinoma | Not specified | IHC | [57] |
†
Adenoma plus cancer.
‡
Immunohistochemistry.
§
Western blotting.
¶
Reverse transcription PCR.
#
Overall.
††
In patients with synchronous carcinoma.
‡‡
In patients with synchronous adenocarcinoma.
§§
In patients responsive to eradication therapy.
¶¶
In patients resistant to eradication therapy.
##
Well differentiated.
†††
Moderately differentiated.
‡‡‡
Poorly differentiated.